Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

This week also saw a notable surge from pharmaceutical company AbbVie, with their drug Skyrizi, which leaped from 32nd to 4th place. PayPal, T-Mobile, and Vicks also made solid showings ...

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.